Investor Presentaiton

Phase 2 interchangeability data support PCV21 as booster Single booster dose 0 Days 30 Toddlers 12-15 Mo 100 PCV21 Formulation #1 n = 35 PCV21 Formulation #2 n = 35 PCV21 Formulation #3 n = 35 primed with 3 doses of PCV13 at 2, 4, 6 months 67 Vaccines Investor Event GMC μg/mL 1 Boosting effect is comparable to PCV13 for common serotypes GMC μg/mL 1 100 10 sanofi Robust immune response for the additional serotypes PCV13 n = 35 H 0,1 0,1 1 3 4 5 6A 6B 7F 9V 14 18C 19A 19F 23F 8 9N 10A 11A 12F 15B 22F 33F PCV21 PCV13

View entire presentation